"The current study was designed to provide sufficient confidence in the new route of administration to support further development. We are excited to have completed this safety study and look forward to evaluating this opportunity to bring benefit to patients with erectile dysfunction who do not respond to approved oral therapies," stated Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin.